Miltefosine (Long Course) for Bolivian Mucosal Leishmaniasis

Phase 1

Completed

• Conditions: Leishmaniasis

• Registration Number: NCT00373568
• Lead Sponsor: AB Foundation

Brief Summary

Miltefosine (longer course) will be used to try to improve the cure rate of mucosal leishmaniasis

Detailed Description

Miltefosine (42 days) will be used to try to improve upon the cure rate with 28 days of drug for bolivian mucosal leishmaniasisi

Study Timeline

• Study Start: 2005-04
• Study First Submitted: 2006-09-07
• Study First Submitted QC: 2006-09-07
• Study First Posted: 2006-09-08
• Study Completion: 2007-12
• Status Verified: 2010-05
• Last Update Submitted: 2010-05-29
• Last Update Posted: 2010-06-02

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 25

Inclusion Criteria

• Mucosal leishmaniasis

Exclusion Criteria

• No comcomitant disease as judged by laboratory and clinical parameters

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
efficacy

Secondary Outcome Measures

Name	Time	Method
safety

Trial Locations

Locations (1)

Palos Blancos; 🇧🇴 Palos Blancos, Bolivia